Physician profile
Manjula Chatterjee
NPI 1164625745
$3,310.53
in general payments reported to CMS, 2019-2025
17 companies · $675 in 2025
The $675 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $44.10 · 2021: $27.22 · 2022: $1,245 · 2023: $224 · 2024: $220 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $980 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $979.87 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $138.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,112.49 | 2021-2024 | Minimed 780g |
| Medtronic Minimed, INC. | $782.98 | 2019 | |
| Pfizer INC. | $253.78 | 2024-2025 | |
| Tolmar, INC. | $243.88 | 2025 | Fensolvi |
| Rhythm Pharmaceuticals, INC. | $233.84 | 2022 | |
| Xeris Pharmaceuticals, INC. | $132.48 | 2023-2025 | Gvoke Hypopen |
| Dexcom, INC. | $125.00 | 2023 | Dexcom G7 Gss (161) |
| Ascendis Pharma Endocrinology INC | $94.11 | 2024-2025 | Skytrofa |
| Endo USA, INC. | $67.30 | 2025 | Supprelin |
| Ferring Pharmaceuticals INC. | $64.15 | 2019-2020 | |
| Abbvie INC. | $56.72 | 2019-2024 | Lupron Depot |
| Beta Bionics, INC. | $34.13 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Merck Sharp & Dohme LLC | $28.43 | 2025 | Keytruda |
| Global Blood Therapeutics, INC. | $23.41 | 2020 | |
| Mirum Pharmaceuticals, INC. | $21.31 | 2025 | Livmarli |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $19.14 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manjula Chatterjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.